This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Docket No. ORT-1550

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application : Daniel Benjamin et al.

Serial No.: 10/037,519

Art Unit: 1743

Filed

: January 3, 2002

Examiner:

For

: ALPHA SYNUCLEIN AGGREGATION ASSAYS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

May 14, 2002 (Date of Deposit)

Mary A. Appollina (Name of applicant, assignee, or Registered Representative)

May 14, 2002

(Date of Signature)

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\square In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under §1.53(d)),
within three months of the date of entry into the national
stage of the above identified application as set forth in
§1.491, or before the mailing date of a first Office Action on
the merits of the above-identified application, or before the
mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \square the
first or _second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of $$180.00$ as set forth in $§1.17(p)$.
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in $\S 1.97(b)$ above but before the mailing date of either a Final
Action under $\S1.113$ or a Notice of Allowance under $\S1.311$, or an
action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or

Please charge Deposit Account No. 10-0750/	/
the fee of \$180.00 as set forth in §1.17(p).	
In accordance with $\S1.97(d)$, this Information	
Disclosure Statement is being filed after the mailing date of	
either a Final Action under §1.113 or a Notice of Allowance	
under §1.311 but before the payment of the Issue Fee.	
Applicant(s) hereby petition(s) for consideration of this	
Information Disclosure Statement. Included are: Statement in	
Accordance with §1.97(e) as set forth below and the fee of	
\$180.00 as set forth in §1.17(p).	
attached Form PTO-1449 are enclosed herewith.	
_	
Copies of references listed on the attached Form PTO-	•
1449 are enclosed herewith EXCEPT THAT:	
☐ In view of the voluminous nature of references	
[list as appropriate], and the likelihood that	
these references are available to the Examiner,	
copies are not enclosed herewith.	
☐ If any of the foregoing publications are not	
available to the Examiner, Applicant will	
endeavor to supply copies at the Examiner's	
request.	
-	
oxtimes There are no listed references which are not in the	
English language.	
The relevance of those listed references which are	
not in the English language is as follows:	

Attached are copies of search re	port(s) from
corresponding patent application(s), which	are listed on the
attached Submission Under MPEP 609 D.	
Attached are the following non-p	
patent applications which may be deemed re	levant, which are
listed on the attached Submission Under MP $$	EP 609 D.
Please charge any deficiency or credi	t any overpayment to
Deposit Account No. 10-0750/ORT-1550/MAA.	This form is
submitted in triplicate.	
Respectfully	submitted,
Mary A. Appo Mary A. Appo Reg. No. 34, Attorney for	

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3742

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

batitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	Valu OMB control number.
Application Number	10/037,519
Filing Date	January 3, 2002
First Named Inventor	Daniel Benjamin et al
Group Art Unit	1743
Examiner Name	
Attorney Docket Number	ORT-1550

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.1	U.S. Patent Document			Date of Publication	Pages, Columns, Lines,
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
	ļ					
 	-					
	,					

FOREIGN PATENT DOCUMENTS Date of Publication Pages, Columns, Lines. Foreign Patent Document of Cited Document where relevant Name of Patentee or 76 Examiner Cite passages or relevant mm-dd-yyyy **Applicant of Cited Document** Initials figures appear KindCode⁵ Office³ Number⁴ No.1 98/59050 12/30/1998 WO **A1** Polymeropoulos WO 99/06545 **A2** Wanker et al. 2/11/1999 WO 00/18917 A2 Biere et al. 4/6/2000 WO 00/20020 **A2** Masliah 4/13/2000

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a valid OMB control number.				
Application Number	10/037,519			
Filing Date	January 3, 2002			
First Named Inventor	Daniel Benjamin et al			
Group Art Unit	1743			
Examiner Name				
Attorney Docket Number	ORT-1550			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	T ²
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	1"
Initials*	No.1	publisher, city and/or country where published	
		Bennett №C, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian №M. Degradation of alpha-synuclein by proteasome. J Biol Chem 1999, 274:33855-8.	
		LeVine, H., Scholten, J.D. Screening for pharmacologic inhibitors of amyloid fibril formation. Weth Enzymol 1999, 309(Ch. 29):467-76.	
		Maroteaux L, Campanelli JT, Scheller RH: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988 Aug;8(8):2804-15.	
		Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999, 274:9843-6.	
		Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wołozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999, 19:5782-91.	
		Polymeropoulos, MiH. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998, 44(3 Suppl 1):S63-4.	
		Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goadert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998, 95:6469-73.	
		₩ood SJ, ₩ypych J, Steavenson S, Louis JC, Citron M, Biere AL. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999, 274:19509-12.	
			L
	<u> </u>		ļ
			├
,			├—
			├
	 		
-			
			
	 		
			_
			t
	-		· · · ·
			

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.